A detailed history of Geode Capital Management, LLC transactions in Nautilus Biotechnology, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,134,731 shares of NAUT stock, worth $3.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,134,731
Previous 1,106,951 2.51%
Holding current value
$3.01 Million
Previous $3.25 Million 18.41%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$2.22 - $3.0 $61,671 - $83,340
27,780 Added 2.51%
1,134,731 $2.66 Million
Q1 2024

May 13, 2024

BUY
$2.41 - $3.18 $100,489 - $132,596
41,697 Added 3.91%
1,106,951 $3.25 Million
Q4 2023

Feb 13, 2024

BUY
$2.34 - $3.39 $118,607 - $171,828
50,687 Added 5.0%
1,065,254 $3.19 Million
Q3 2023

Nov 13, 2023

BUY
$2.87 - $3.94 $23,249 - $31,917
8,101 Added 0.8%
1,014,567 $3.21 Million
Q2 2023

Aug 11, 2023

BUY
$2.21 - $4.52 $28,243 - $57,765
12,780 Added 1.29%
1,006,466 $3.9 Million
Q1 2023

May 15, 2023

BUY
$1.67 - $2.77 $54,806 - $90,905
32,818 Added 3.42%
993,686 $2.75 Million
Q4 2022

Feb 13, 2023

BUY
$1.55 - $2.47 $8,988 - $14,323
5,799 Added 0.61%
960,868 $1.73 Million
Q3 2022

Nov 14, 2022

BUY
$1.96 - $3.13 $8,408 - $13,427
4,290 Added 0.45%
955,069 $2.02 Million
Q2 2022

Aug 12, 2022

BUY
$2.64 - $4.84 $1.12 Million - $2.05 Million
424,473 Added 80.65%
950,779 $2.56 Million
Q1 2022

May 13, 2022

BUY
$3.5 - $5.3 $108,878 - $164,872
31,108 Added 6.28%
526,306 $2.28 Million
Q4 2021

Feb 11, 2022

BUY
$4.45 - $6.21 $486,505 - $678,920
109,327 Added 28.33%
495,198 $2.57 Million
Q3 2021

Nov 12, 2021

BUY
$6.14 - $10.1 $1.97 Million - $3.24 Million
320,474 Added 490.04%
385,871 $2.37 Million
Q2 2021

Aug 13, 2021

BUY
$9.04 - $14.19 $591,188 - $927,983
65,397 New
65,397 $660,000

Others Institutions Holding NAUT

About Nautilus Biotechnology, Inc.


  • Ticker NAUT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,663,000
  • Market Cap $330M
  • Description
  • Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was found...
More about NAUT
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.